A Biospecimen Collection Study of Leukapheresis-Derived Circulating Tumor Cells, Immune Cells, and Progenitor Cells.
Recruiting
1,500 enrolled
AUGMENT-101
Phase 1/2 Recruiting
447 enrolled 2 FDA
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Phase 1/2 Recruiting
231 enrolled
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Phase 2/3 Recruiting
316 enrolled
KEYNOTE-E12
Phase 1 Recruiting
78 enrolled
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Phase 2/3 Recruiting
806 enrolled
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
442 enrolled
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Phase 1 Recruiting
134 enrolled
CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
SYNERGY-101
Phase 1/2 Recruiting
364 enrolled
MAHOGANY
Phase 3 Recruiting
780 enrolled
aCCeleR8-001
Phase 1/2 Recruiting
282 enrolled
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
Phase 4 Recruiting
46 enrolled
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
CEMI-LUNG
Recruiting
500 enrolled
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Phase 1/2 Recruiting
87 enrolled
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting
163 enrolled
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Phase 1 Recruiting
210 enrolled
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
290 enrolled
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Phase 3 Recruiting
416 enrolled
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1 Recruiting
187 enrolled
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Phase 1 Recruiting
308 enrolled
PROSPER
Phase 1/2 Recruiting
403 enrolled
A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
189 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
140 enrolled
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Phase 3 Recruiting
500 enrolled
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers
Phase 1 Recruiting
30 enrolled
ALPHA3
Phase 2 Recruiting
250 enrolled
ABLE-32
Phase 3 Recruiting
454 enrolled
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Phase 3 Recruiting
1,018 enrolled
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Phase 1 Recruiting
514 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
80 enrolled
DETECT-ME
Recruiting
700 enrolled
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Phase 1 Recruiting
90 enrolled
CTC-EXPRESS
Recruiting
187 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
AMPLIFY
Phase 3 Recruiting
220 enrolled
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 3 Recruiting
500 enrolled
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Phase 3 Recruiting
183 enrolled
MOMENTUM
Phase 1/2 Recruiting
84 enrolled
BA-004
Phase NA Recruiting
2,063 enrolled
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Phase 3 Recruiting
400 enrolled
TB06
Phase 3 Recruiting
100 enrolled
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Phase 1/2 Recruiting
420 enrolled
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Phase 1 Recruiting
86 enrolled
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3 Recruiting
500 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
386 enrolled
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
Phase 1 Recruiting
144 enrolled